跳至主要内容
临床试验/CTRI/2012/05/002669
CTRI/2012/05/002669
Other
未知

Multisensor Chronic Evaluations in Ambulatory Heart Failure Patients - MultiSENSE

Guidant Europe a Boston Scientific Company0 个研究点目标入组 990 人待定

概览

阶段
未知
干预措施
未指定
疾病 / 适应症
Health Condition 1: null- Heart Failure
发起方
Guidant Europe a Boston Scientific Company
入组人数
990
状态
Other
最后更新
4年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
4年前
研究类型
Interventional

研究者

发起方
Guidant Europe a Boston Scientific Company

入排标准

入选标准

  • 1\. Age 18 or above, or of legal age to give informed consent specific to state and national law.
  • 2\. Willing and capable of returning for all follow\-up visits and emergency care at the investigational center as medically appropriate.
  • 3\. Willing to participate in all testing associated with this clinical investigation at an approved clinical investigational center.
  • 4\. Currently implanted with a CRT\-D system including a COGNIS device (model N119, N120, P107 or P108\) with RA, RV and LV leads
  • 5\. Currently classified as NYHA Class II, III or IV within the last six months

排除标准

  • 1\. Inability or refusal to sign the Subject Informed Consent.
  • 2\. Inability or refusal to comply with the follow\-up schedule.
  • 3\. Documented as pacemaker dependent.
  • 4\. Unable to rest comfortably in a semi\-recumbent position for up to 20 minutes.
  • 5\. Implanted with active Medtronic Fidelis lead models: 6930, 6931, 6948 or 6949\.
  • 6\. Currently implanted with unipolar RA, RV, or LV leads.
  • 7\. LV sensitivity programmed to less than 0\.7 mV AGC.
  • 8\. Subjects that have a history of appropriate Tachycardia Therapy (external or implanted) for rates 165 bpm within 1 week prior to enrollment.
  • 9\. Device battery status indicates approximate time to explant 2 years.
  • 10\. Likely to undergo lead or PG revision during the course of the study as determined by the investigator.

结局指标

主要结局

未指定

相似试验